In esophageal cancer treated with neoadjuvant chemoradiation, combined FOXO plus TGFβ pathway activity was associated with favorable outcome, while loss of FOXO and TGFβ pathway activity was associated with increased recurrence rate (Creemers et al., 2018). The gene discussed is TGFB1; the disease is esophageal cancer.